1. Home
  2. AMAL vs DRTS Comparison

AMAL vs DRTS Comparison

Compare AMAL & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amalgamated Financial Corp. (DE)

AMAL

Amalgamated Financial Corp. (DE)

HOLD

Current Price

$49.03

Market Cap

1.3B

Sector

Finance

ML Signal

HOLD

Logo Alpha Tau Medical Ltd.

DRTS

Alpha Tau Medical Ltd.

HOLD

Current Price

$14.39

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMAL
DRTS
Founded
1923
2015
Country
United States
Israel
Employees
N/A
N/A
Industry
Commercial Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.0B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
AMAL
DRTS
Price
$49.03
$14.39
Analyst Decision
Hold
Strong Buy
Analyst Count
2
3
Target Price
$36.00
$8.67
AVG Volume (30 Days)
135.2K
498.4K
Earning Date
04-23-2026
05-18-2026
Dividend Yield
1.68%
N/A
EPS Growth
N/A
N/A
EPS
1.99
N/A
Revenue
N/A
N/A
Revenue This Year
$21.18
N/A
Revenue Next Year
$6.55
$699.98
P/E Ratio
$24.65
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.13
$3.06
52 Week High
$51.59
$14.75

Technical Indicators

Market Signals
Indicator
AMAL
DRTS
Relative Strength Index (RSI) 49.67 62.77
Support Level $36.50 $6.59
Resistance Level $51.25 $14.75
Average True Range (ATR) 0.84 0.67
MACD -0.27 0.08
Stochastic Oscillator 16.59 89.25

Price Performance

Historical Comparison
AMAL
DRTS

About AMAL Amalgamated Financial Corp. (DE)

Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.

About DRTS Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.

Share on Social Networks: